{
    "originUrl": "https://www.astrazeneca.com",
    "customerName": "Astrazeneca-143",
    "urls": [
      {
        "url": "https://www.astrazeneca.com/country-sites/thailand/press-releases/LAAB-enhancing-immunity-for-the-elderly-th.html",
        "source": "SITEMAPS",
        "id": "138ba5331ac9a87f93a7e004b7cd6981a8ff5259",
        "targetPath": "/country-sites/thailand/press-releases/laab-enhancing-immunity-for-the-elderly-th",
        "group_size": 155
      },
      {
        "url": "https://www.astrazeneca.com/media-centre/press-releases/2020/astrazeneca-acquires-oral-pcsk9-inhibitor-programme-from-dogma-therapeutics.html",
        "source": "SITEMAPS",
        "id": "369157858de1405c40dd3b3d9fa34dbd5905c5af",
        "targetPath": "/media-centre/press-releases/2020/astrazeneca-acquires-oral-pcsk9-inhibitor-programme-from-dogma-therapeutics",
        "group_size": 139
      },
      {
        "url": "https://www.astrazeneca.com/media-centre/press-releases/2022/acquisition-of-teneotwo-for-its-clinical-stage-t-cell-engager-completed.html",
        "source": "SITEMAPS",
        "id": "594ad0436270eee386d01eef2a72376d019fa603",
        "targetPath": "/media-centre/press-releases/2022/acquisition-of-teneotwo-for-its-clinical-stage-t-cell-engager-completed",
        "group_size": 135
      },
      {
        "url": "https://www.astrazeneca.com/media-centre/press-releases/2021/acquisition-of-alexion-completed.html",
        "source": "SITEMAPS",
        "id": "6b5765d69490a139b5eb4fd5a963f0ff2c3ceee5",
        "targetPath": "/media-centre/press-releases/2021/acquisition-of-alexion-completed",
        "group_size": 131
      },
      {
        "url": "https://www.astrazeneca.com/media-centre/medical-releases/Anifrolumab-reduces-disease-flares-in-patients-with-systemic-lupus-erythematosus-while-allowing-oral-corticosteroid-tapering.html",
        "source": "SITEMAPS",
        "id": "05ba988a4986d317af7fc6b2f76df3efb939d079",
        "targetPath": "/media-centre/medical-releases/anifrolumab-reduces-disease-flares-in-patients-with-systemic-lupus-erythematosus-while-allowing-oral-corticosteroid-tapering",
        "group_size": 124
      },
      {
        "url": "https://www.astrazeneca.com/media-centre/press-releases/2023/9m-and-q3-2023-results.html",
        "source": "SITEMAPS",
        "id": "f21d0aec08ff6a4b5cdb11f5e78177a0b76698b8",
        "targetPath": "/media-centre/press-releases/2023/9m-and-q3-2023-results",
        "group_size": 116
      },
      {
        "url": "https://www.astrazeneca.com/media-centre/press-releases/2024/9m-and-q3-2024-results.html",
        "source": "SITEMAPS",
        "id": "4d3a5afd17c4e01f7a838b517d0a5b99a79f4fbd",
        "targetPath": "/media-centre/press-releases/2024/9m-and-q3-2024-results",
        "group_size": 108
      },
      {
        "url": "https://www.astrazeneca.com/media-centre/press-releases/2019/H1-2019-results.html",
        "source": "SITEMAPS",
        "id": "5956d5c5ba643f03545efbbd6748768801d4e4a4",
        "targetPath": "/media-centre/press-releases/2019/h1-2019-results",
        "group_size": 106
      },
      {
        "url": "https://www.astrazeneca.com/media-centre/press-releases/2014/astrazenca-scientific-leadership-growth-jp-morgan-healthcare-conference-14012014.html",
        "source": "SITEMAPS",
        "id": "f5c2805200770980fc13478385df19eac91cd5a3",
        "targetPath": "/media-centre/press-releases/2014/astrazenca-scientific-leadership-growth-jp-morgan-healthcare-conference-14012014",
        "group_size": 105
      },
      {
        "url": "https://www.astrazeneca.com/media-centre/press-releases/2015/-fda-advisory-committee-recommends-the-approval-of-lesinurad-for-gout-patients-23102015.html",
        "source": "SITEMAPS",
        "id": "3d4e8166302a9ce5c5b626c2e549985f22506f06",
        "targetPath": "/media-centre/press-releases/2015/fda-advisory-committee-recommends-the-approval-of-lesinurad-for-gout-patients-23102015",
        "group_size": 103
      },
      {
        "url": "https://www.astrazeneca.com/our-company/our-people/Elisabeth-Bjork.html",
        "source": "SITEMAPS",
        "id": "216b277f1dddfe887dce798abf575a44d227c22a",
        "targetPath": "/our-company/our-people/elisabeth-bjork",
        "group_size": 101
      },
      {
        "url": "https://www.astrazeneca.com/media-centre/press-releases/2018/1st-line-tagrisso-demonstrates-sustained-benefit-post-progression-in-patients-with-egfr-mutated-non-small-cell-lung-cancer-13042018.html",
        "source": "SITEMAPS",
        "id": "cb15803b7f32c7513c1483368f1fa02417166b0b",
        "targetPath": "/media-centre/press-releases/2018/1st-line-tagrisso-demonstrates-sustained-benefit-post-progression-in-patients-with-egfr-mutated-non-small-cell-lung-cancer-13042018",
        "group_size": 90
      },
      {
        "url": "https://www.astrazeneca.com/media-centre/press-releases/2017/Siliq-brodalumab-approved-by-the-US-FDA-for-adult-patients-with-moderate-to-severe-plaque-psoriasis-160220170.html",
        "source": "SITEMAPS",
        "id": "b62b80271b53bda7e5b6fffba8986d5a006154dc",
        "targetPath": "/media-centre/press-releases/2017/siliq-brodalumab-approved-by-the-us-fda-for-adult-patients-with-moderate-to-severe-plaque-psoriasis-160220170",
        "group_size": 82
      },
      {
        "url": "https://www.astrazeneca.com/media-centre/press-releases/2016/AstraZeneca-and-Eli-Lilly-and-company-announce-continuation-of-pivotal-clinical-trial-for-people-with-early-alzheimers-disease-08042016.html",
        "source": "SITEMAPS",
        "id": "16bcf88b52947797ae2e71bf85f49db824a1d4ce",
        "targetPath": "/media-centre/press-releases/2016/astrazeneca-and-eli-lilly-and-company-announce-continuation-of-pivotal-clinical-trial-for-people-with-early-alzheimers-disease-08042016",
        "group_size": 77
      },
      {
        "url": "https://www.astrazeneca.com/media-centre/press-releases/2013/astrazeneca-accelerated-oncology-pipeline-2013-asco-annual-meeting-16052013.html",
        "source": "SITEMAPS",
        "id": "d3ec1d2248750a6cf85e8170bcaec59ef63b3674",
        "targetPath": "/media-centre/press-releases/2013/astrazeneca-accelerated-oncology-pipeline-2013-asco-annual-meeting-16052013",
        "group_size": 70
      },
      {
        "url": "https://www.astrazeneca.com/media-centre/press-releases/2010/24-Week-Phase-3-Study-Found-Investigational-Drug-Dapagliflozin-Improved-Glycosylated-Hemoglobin-HbA1c-When-Added-to-Glimepiride-in-Adults-with-Type-2-Diabetes-Mellitus-20092010.html",
        "source": "SITEMAPS",
        "id": "316a599a072afdc0e492b93e56f9c4816d44ceca",
        "targetPath": "/media-centre/press-releases/2010/24-week-phase-3-study-found-investigational-drug-dapagliflozin-improved-glycosylated-hemoglobin-hba1c-when-added-to-glimepiride-in-adults-with-type-2-diabetes-mellitus-20092010",
        "group_size": 62
      },
      {
        "url": "https://www.astrazeneca.com/media-centre/press-releases/2009/Advisory-Committee-Briefing-Materials-For-Crestor-sND-11122009.html",
        "source": "SITEMAPS",
        "id": "4a18869e5e6efb4e24d044e4ad15653523188636",
        "targetPath": "/media-centre/press-releases/2009/advisory-committee-briefing-materials-for-crestor-snd-11122009",
        "group_size": 60
      },
      {
        "url": "https://www.astrazeneca.com/media-centre/press-releases/2025/acquisition-of-esobiotec-completed.html",
        "source": "SITEMAPS",
        "id": "dad45158b690e98454f5a43385d488f64ffa5952",
        "targetPath": "/media-centre/press-releases/2025/acquisition-of-esobiotec-completed",
        "group_size": 58
      },
      {
        "url": "https://www.astrazeneca.com/media-centre/press-releases/2011/-fda-accepts-new-drug-application-for-investigational-compound-08032011.html",
        "source": "SITEMAPS",
        "id": "73e24936c46ffd55c6c3e7e27709a93e50f6984a",
        "targetPath": "/media-centre/press-releases/2011/fda-accepts-new-drug-application-for-investigational-compound-08032011",
        "group_size": 49
      },
      {
        "url": "https://www.astrazeneca.com/media-centre/press-releases/2012/Alzheimers-cancer-and-rare-disease-research-to-benefit-from-landmark-MRC-AstraZeneca-compound-collaboration-31102012.html",
        "source": "SITEMAPS",
        "id": "bc92da447fe958dabe55324c3b4b04fb8107c225",
        "targetPath": "/media-centre/press-releases/2012/alzheimers-cancer-and-rare-disease-research-to-benefit-from-landmark-mrc-astrazeneca-compound-collaboration-31102012",
        "group_size": 46
      },
      {
        "url": "https://www.astrazeneca.com/investor-relations/9m-and-q3-2023-results.html",
        "source": "SITEMAPS",
        "id": "ddc0efbc4d896d4a35361012354daadded8fcba4",
        "targetPath": "/investor-relations/9m-and-q3-2023-results",
        "group_size": 34
      },
      {
        "url": "https://www.astrazeneca.com/what-science-can-do/topics/disease-understanding/Hitting-the-bullseye-finding-better-targets-for-drug-development.html",
        "source": "SITEMAPS",
        "id": "df9e28a589e8fe418aa881e6a1ddd1a437aef472",
        "targetPath": "/what-science-can-do/topics/disease-understanding/hitting-the-bullseye-finding-better-targets-for-drug-development",
        "group_size": 27
      },
      {
        "url": "https://www.astrazeneca.com/country-sites/african-cluster.html",
        "source": "SITEMAPS",
        "id": "29aedc696134baa1fd1277626bf3f205391baf42",
        "targetPath": "/country-sites/african-cluster",
        "group_size": 23
      },
      {
        "url": "https://www.astrazeneca.com/media-centre/articles/2024/AI-solutions-healthcare-emerging-markets.html",
        "source": "SITEMAPS",
        "id": "e6c5af00032d80ac0c659fe94c007f9011534ad0",
        "targetPath": "/media-centre/articles/2024/ai-solutions-healthcare-emerging-markets",
        "group_size": 22
      },
      {
        "url": "https://www.astrazeneca.com/what-science-can-do/topics/next-generation-therapeutics/Accelerating-innovation-to-transform-cancer-care.html",
        "source": "SITEMAPS",
        "id": "dd2be512ee0bd7a27f4e77f1118800aa69ef3c0f",
        "targetPath": "/what-science-can-do/topics/next-generation-therapeutics/accelerating-innovation-to-transform-cancer-care",
        "group_size": 22
      },
      {
        "url": "https://www.astrazeneca.com/media-centre/articles/2023/advancing-the-science-in-immune-mediated-diseases.html",
        "source": "SITEMAPS",
        "id": "a6bad79ffed7c2d8f98418067e757f823364e95b",
        "targetPath": "/media-centre/articles/2023/advancing-the-science-in-immune-mediated-diseases",
        "group_size": 20
      },
      {
        "url": "https://www.astrazeneca.com/r-d/next-generation-therapeutics/T-cell-engager.html",
        "source": "SITEMAPS",
        "id": "54110a609eef621083b78be4f5a00cf7e518cfa5",
        "targetPath": "/r-d/next-generation-therapeutics/t-cell-engager",
        "group_size": 17
      },
      {
        "url": "https://www.astrazeneca.com/media-centre/articles/2022/AZ-Forest-New-Partnership-Commitments.html",
        "source": "SITEMAPS",
        "id": "90b323a9c8e9765986c93598cb6c4d48fe5f94fe",
        "targetPath": "/media-centre/articles/2022/az-forest-new-partnership-commitments",
        "group_size": 16
      },
      {
        "url": "https://www.astrazeneca.com/media-centre/press-releases/2009.html",
        "source": "SITEMAPS",
        "id": "c56d55f3f120ad6b93a125b800214ebbf7a72cb5",
        "targetPath": "/media-centre/press-releases/2009",
        "group_size": 16
      },
      {
        "url": "https://www.astrazeneca.com/what-science-can-do/topics/technologies/Kidney-disease-research-organoids.html",
        "source": "SITEMAPS",
        "id": "5011bbfa544f739092598574c0f664fd0c50ae8b",
        "targetPath": "/what-science-can-do/topics/technologies/kidney-disease-research-organoids",
        "group_size": 14
      },
      {
        "url": "https://www.astrazeneca.com/what-science-can-do/topics/clinical-innovation/Streamlining-clinical-trials-through-digital-solutions.html",
        "source": "SITEMAPS",
        "id": "9d3dca0bc90043b84ea5d548a58f4c856a60cde3",
        "targetPath": "/what-science-can-do/topics/clinical-innovation/streamlining-clinical-trials-through-digital-solutions",
        "group_size": 14
      },
      {
        "url": "https://www.astrazeneca.com/country-sites/singapore/press-releases/astrazeneca-and-lucence-collaborate-in-south-east-asia.html",
        "source": "SITEMAPS",
        "id": "5e157b87526f073198ff8d10cbe7c59d798fbd84",
        "targetPath": "/country-sites/singapore/press-releases/astrazeneca-and-lucence-collaborate-in-south-east-asia",
        "group_size": 14
      },
      {
        "url": "https://www.astrazeneca.com/our-therapy-areas/oncology/Liver-cancer.html",
        "source": "SITEMAPS",
        "id": "f5d200178da7956b902723b27b676a5039c0ca72",
        "targetPath": "/our-therapy-areas/oncology/liver-cancer",
        "group_size": 13
      },
      {
        "url": "https://www.astrazeneca.com/media-centre/articles/2022.html",
        "source": "SITEMAPS",
        "id": "839c321ab001b7c11c693c4d70fa0c27efc16ba2",
        "targetPath": "/media-centre/articles/2022",
        "group_size": 12
      },
      {
        "url": "https://www.astrazeneca.com/what-science-can-do/topics/data-science-ai/biologics-discovery.html",
        "source": "SITEMAPS",
        "id": "92396c50aeb8f4c6c78841164b8d233877c562c8",
        "targetPath": "/what-science-can-do/topics/data-science-ai/biologics-discovery",
        "group_size": 11
      },
      {
        "url": "https://www.astrazeneca.com/partnering/Externally-sponsored-scientific-research-training-centre.html",
        "source": "SITEMAPS",
        "id": "40f51abece68adcfb076c6a1143519ecc5f73f4a",
        "targetPath": "/partnering/externally-sponsored-scientific-research-training-centre",
        "group_size": 11
      },
      {
        "url": "https://www.astrazeneca.com/country-sites/thailand/press-release/an-open-letter-to-the-people-of-thailand-en.html",
        "source": "SITEMAPS",
        "id": "76fec331fa19d7961062e7610a163417397f8fde",
        "targetPath": "/country-sites/thailand/press-release/an-open-letter-to-the-people-of-thailand-en",
        "group_size": 11
      },
      {
        "url": "https://www.astrazeneca.com/az-suppliers/az-coupa-supplier/CSP.html",
        "source": "SITEMAPS",
        "id": "854c183ac58ae40dd866a625dc940c4233951f4c",
        "targetPath": "/az-suppliers/az-coupa-supplier/csp",
        "group_size": 11
      },
      {
        "url": "https://www.astrazeneca.com/what-science-can-do/topics/sustainability/biocatalysis-perform-sustainable-chemical-reactions.html",
        "source": "SITEMAPS",
        "id": "e38c673ad2ba91f5ae110371f5b43892ec87b62b",
        "targetPath": "/what-science-can-do/topics/sustainability/biocatalysis-perform-sustainable-chemical-reactions",
        "group_size": 10
      },
      {
        "url": "https://www.astrazeneca.com/investor-relations/annual-reports/annual-report-2015.html",
        "source": "SITEMAPS",
        "id": "bfebda4a14cfe7c247ac85581b0c880d55758d68",
        "targetPath": "/investor-relations/annual-reports/annual-report-2015",
        "group_size": 10
      },
      {
        "url": "https://www.astrazeneca.com/media-centre/archive.html",
        "source": "SITEMAPS",
        "id": "9ee6b80b83b34018115e6695855fb4f3930602c8",
        "targetPath": "/media-centre/archive",
        "group_size": 9
      },
      {
        "url": "https://www.astrazeneca.com/our-therapy-areas/biopharmaceuticals.html",
        "source": "SITEMAPS",
        "id": "6b36adc4f20c2cdd0a5ce6a82de01a0b6b32a5b0",
        "targetPath": "/our-therapy-areas/biopharmaceuticals",
        "group_size": 9
      },
      {
        "url": "https://www.astrazeneca.com/r-d/our-technologies/acoustic-tube-sample-management.html",
        "source": "SITEMAPS",
        "id": "84d440feb3393987414eabb8d7f59bccad0a9c88",
        "targetPath": "/r-d/our-technologies/acoustic-tube-sample-management",
        "group_size": 8
      },
      {
        "url": "https://www.astrazeneca.com/patient-reported-outcomes/cardiovascular.html",
        "source": "SITEMAPS",
        "id": "676941109a4b9360300e6d9b9515fc14b5d2462e",
        "targetPath": "/patient-reported-outcomes/cardiovascular",
        "group_size": 7
      },
      {
        "url": "https://www.astrazeneca.com/country-sites/thailand/an-open-letter-to-the-people-of-thailand-en.html",
        "source": "SITEMAPS",
        "id": "9a5dff9d5dfaf84d2fbe7f83e66c5e4eae7ba0e4",
        "targetPath": "/country-sites/thailand/an-open-letter-to-the-people-of-thailand-en",
        "group_size": 6
      },
      {
        "url": "https://www.astrazeneca.com/az-suppliers/az-coupa-supplier/faq/CSP-linked.html",
        "source": "SITEMAPS",
        "id": "758da2ada74e200e6223ca13f42cf3abedf1e3cd",
        "targetPath": "/az-suppliers/az-coupa-supplier/faq/csp-linked",
        "group_size": 6
      },
      {
        "url": "https://www.astrazeneca.com/our-company/Contact-us.html",
        "source": "SITEMAPS",
        "id": "d12a0c826e0b2fcc99845b44c5d31183aea3fa8e",
        "targetPath": "/our-company/contact-us",
        "group_size": 5
      },
      {
        "url": "https://www.astrazeneca.com/sustainability/resources/archive.html",
        "source": "SITEMAPS",
        "id": "9d5f73e5bd647cdcd7b63a2affd1df7dd9631984",
        "targetPath": "/sustainability/resources/archive",
        "group_size": 5
      },
      {
        "url": "https://www.astrazeneca.com/media-centre/articles/2025/advancing-sustainable-respiratory-care-with-the-transition-to-pMDIs-with-near-zero-GWP-propellant.html",
        "source": "SITEMAPS",
        "id": "c1658d5bb8a819cf7a6799c14ce382eb5dc73f59",
        "targetPath": "/media-centre/articles/2025/advancing-sustainable-respiratory-care-with-the-transition-to-pmdis-with-near-zero-gwp-propellant",
        "group_size": 5
      },
      {
        "url": "https://www.astrazeneca.com/",
        "source": "SITEMAPS",
        "id": "ecda591b69347eb7a8a22676c8ef671a2a80646c",
        "targetPath": "/",
        "group_size": 1
      },
      {
        "url": "https://www.astrazeneca.com/astrazeneca-exchange.html",
        "source": "SITEMAPS",
        "id": "31ef1b2f96cec4c9eba7a188f2e86d5072275270",
        "targetPath": "/astrazeneca-exchange",
        "group_size": 1
      },
      {
        "url": "https://www.astrazeneca.com/az-suppliers/az-coupa-supplier.html",
        "source": "SITEMAPS",
        "id": "3ead70c0c95ff959e114278689c39ca6855a0cf2",
        "targetPath": "/az-suppliers/az-coupa-supplier",
        "group_size": 1
      },
      {
        "url": "https://www.astrazeneca.com/az-suppliers/supplier-contact-information.html",
        "source": "SITEMAPS",
        "id": "dbb14d23ae12ac40612761d2c6bef72eceb52aa1",
        "targetPath": "/az-suppliers/supplier-contact-information",
        "group_size": 1
      },
      {
        "url": "https://www.astrazeneca.com/country-sites.html",
        "source": "SITEMAPS",
        "id": "764d91667417a848035aa3491ba064933c44e378",
        "targetPath": "/country-sites",
        "group_size": 1
      },
      {
        "url": "https://www.astrazeneca.com/country-sites/egypt/az-egypt-statement-30052018.html",
        "source": "SITEMAPS",
        "id": "583b91277e354fa6dd0e4f4006025765bf56637a",
        "targetPath": "/country-sites/egypt/az-egypt-statement-30052018",
        "group_size": 1
      },
      {
        "url": "https://www.astrazeneca.com/country-sites/singapore/press-releases.html",
        "source": "SITEMAPS",
        "id": "9a77c8fdb883c78fab34de690b3ecd770888c5ae",
        "targetPath": "/country-sites/singapore/press-releases",
        "group_size": 1
      },
      {
        "url": "https://www.astrazeneca.com/country-sites/taiwan/23032020.html",
        "source": "SITEMAPS",
        "id": "014a3dfd4fcedcd8f0b942a38adb0f10f74da6c2",
        "targetPath": "/country-sites/taiwan/23032020",
        "group_size": 1
      },
      {
        "url": "https://www.astrazeneca.com/country-sites/vietnam/legal-notice-and-terms-of-use.html",
        "source": "SITEMAPS",
        "id": "2b33bab7bee63914970f6050fd287606465d35ca",
        "targetPath": "/country-sites/vietnam/legal-notice-and-terms-of-use",
        "group_size": 1
      },
      {
        "url": "https://www.astrazeneca.com/global.html",
        "source": "SITEMAPS",
        "id": "c048e347d41e136f3593177c23f49cd2efede240",
        "targetPath": "/global",
        "group_size": 1
      },
      {
        "url": "https://www.astrazeneca.com/global/en.html",
        "source": "SITEMAPS",
        "id": "d96f62c86d372dcce2d5d53945e0543594ed97a3",
        "targetPath": "/global/en",
        "group_size": 1
      },
      {
        "url": "https://www.astrazeneca.com/global/en/AstraZeneca-Websites.html",
        "source": "SITEMAPS",
        "id": "b1436fd8d3db99527f4bdb299db31e03586cbb86",
        "targetPath": "/global/en/astrazeneca-websites",
        "group_size": 1
      },
      {
        "url": "https://www.astrazeneca.com/global/en/Resources.html",
        "source": "SITEMAPS",
        "id": "837e875842867fbf0eed145c3f8e2417e94ddd7f",
        "targetPath": "/global/en/resources",
        "group_size": 1
      },
      {
        "url": "https://www.astrazeneca.com/global/en/annualreport.html",
        "source": "SITEMAPS",
        "id": "7a9837e2d0ba2a29b06f5e45d238002e9040aa01",
        "targetPath": "/global/en/annualreport",
        "group_size": 1
      },
      {
        "url": "https://www.astrazeneca.com/global/en/sitemap.html",
        "source": "SITEMAPS",
        "id": "85738b3a87f8659627c7a9c8ae9a865f5391d7bc",
        "targetPath": "/global/en/sitemap",
        "group_size": 1
      },
      {
        "url": "https://www.astrazeneca.com/government-contract-t-cs.html",
        "source": "SITEMAPS",
        "id": "aaa404414debc656b470e7b38212cdc457aba6ff",
        "targetPath": "/government-contract-t-cs",
        "group_size": 1
      },
      {
        "url": "https://www.astrazeneca.com/investor-relations.html",
        "source": "SITEMAPS",
        "id": "d44737938df5af955ed1650d9bcbc69512dba3d8",
        "targetPath": "/investor-relations",
        "group_size": 1
      },
      {
        "url": "https://www.astrazeneca.com/investor-relations/annual-reports/annual-report-2015/cautionary-statement.html",
        "source": "SITEMAPS",
        "id": "e42c7c99cc8eb6c6c63f430c33619c3afb46ec9f",
        "targetPath": "/investor-relations/annual-reports/annual-report-2015/cautionary-statement",
        "group_size": 1
      },
      {
        "url": "https://www.astrazeneca.com/investor-relations/annual-reports/annual-report-2015/reader-information.html",
        "source": "SITEMAPS",
        "id": "3d75fe57e943dccf4f562c2caba1753220745af7",
        "targetPath": "/investor-relations/annual-reports/annual-report-2015/reader-information",
        "group_size": 1
      },
      {
        "url": "https://www.astrazeneca.com/investor-relations/annual-reports/annual-report-2016/annual-report-and-cautionary-statement.html",
        "source": "SITEMAPS",
        "id": "abd2f4696f15d245d7d76119a0dd8b63a0e24cb9",
        "targetPath": "/investor-relations/annual-reports/annual-report-2016/annual-report-and-cautionary-statement",
        "group_size": 1
      },
      {
        "url": "https://www.astrazeneca.com/investor-relations/annual-reports/annual-report-2016/contact-information.html",
        "source": "SITEMAPS",
        "id": "8e31bc93dce3c232d3d9336f1d429319fdc02272",
        "targetPath": "/investor-relations/annual-reports/annual-report-2016/contact-information",
        "group_size": 1
      },
      {
        "url": "https://www.astrazeneca.com/investor-relations/debt-investors/emtn-programme.html",
        "source": "SITEMAPS",
        "id": "e5a964214edbd0292d99e2199a13d744a0f180ff",
        "targetPath": "/investor-relations/debt-investors/emtn-programme",
        "group_size": 1
      },
      {
        "url": "https://www.astrazeneca.com/investor-relations/results-and-presentations/archive.html",
        "source": "SITEMAPS",
        "id": "af0f221a3f0d02de6c967a49423f8f7c4e2d2784",
        "targetPath": "/investor-relations/results-and-presentations/archive",
        "group_size": 1
      },
      {
        "url": "https://www.astrazeneca.com/legal-notice-and-terms-of-use.html",
        "source": "SITEMAPS",
        "id": "c8295d1307db3896de62cc81f76082e53864da83",
        "targetPath": "/legal-notice-and-terms-of-use",
        "group_size": 1
      },
      {
        "url": "https://www.astrazeneca.com/legal-notice-and-terms-of-use/id.html",
        "source": "SITEMAPS",
        "id": "1b51a4ebe7d82e8aa84e6c50206d447b145ed257",
        "targetPath": "/legal-notice-and-terms-of-use/id",
        "group_size": 1
      },
      {
        "url": "https://www.astrazeneca.com/media-centre.html",
        "source": "SITEMAPS",
        "id": "024dc5b113f46af863f9dcf3e8afcbe78cdb7723",
        "targetPath": "/media-centre",
        "group_size": 1
      },
      {
        "url": "https://www.astrazeneca.com/our-company.html",
        "source": "SITEMAPS",
        "id": "7e2fb43ade2f44149cabf64ae6b0a0bbedf2949e",
        "targetPath": "/our-company",
        "group_size": 1
      },
      {
        "url": "https://www.astrazeneca.com/our-company/leadership/susan-galbraith.html",
        "source": "SITEMAPS",
        "id": "c201a90b3550791f036e75486485ad30a9a64614",
        "targetPath": "/our-company/leadership/susan-galbraith",
        "group_size": 1
      },
      {
        "url": "https://www.astrazeneca.com/our-company/our-locations/cambridge.html",
        "source": "SITEMAPS",
        "id": "ef2eb33a8b350aada22540f73cd1c7f835e20dd6",
        "targetPath": "/our-company/our-locations/cambridge",
        "group_size": 1
      },
      {
        "url": "https://www.astrazeneca.com/our-company/our-locations/gaithersburg.html",
        "source": "SITEMAPS",
        "id": "b7fdd63eba8bc3be44942880e0ba41c2f2a9c0d5",
        "targetPath": "/our-company/our-locations/gaithersburg",
        "group_size": 1
      },
      {
        "url": "https://www.astrazeneca.com/our-company/our-locations/gothenburg.html",
        "source": "SITEMAPS",
        "id": "69a5dfae5abfc4691a0324341266aa5c66c8d395",
        "targetPath": "/our-company/our-locations/gothenburg",
        "group_size": 1
      },
      {
        "url": "https://www.astrazeneca.com/our-therapy-areas.html",
        "source": "SITEMAPS",
        "id": "4b0869c5841c1eb4caf38510ae9beb2c1dcb220e",
        "targetPath": "/our-therapy-areas",
        "group_size": 1
      },
      {
        "url": "https://www.astrazeneca.com/our-therapy-areas/cardiovascular-renal-and-metabolism/metabolism.html",
        "source": "SITEMAPS",
        "id": "718cc55479afe9175958ad751f61a90727242bdd",
        "targetPath": "/our-therapy-areas/cardiovascular-renal-and-metabolism/metabolism",
        "group_size": 1
      },
      {
        "url": "https://www.astrazeneca.com/our-therapy-areas/cardiovascular-renal-and-metabolism/renal.html",
        "source": "SITEMAPS",
        "id": "cbe19d9f28a3913724122f3f2be63d099afdb04e",
        "targetPath": "/our-therapy-areas/cardiovascular-renal-and-metabolism/renal",
        "group_size": 1
      },
      {
        "url": "https://www.astrazeneca.com/our-therapy-areas/respiratory-and-immunology/epithelial-science.html",
        "source": "SITEMAPS",
        "id": "f18fe6c650973a5bdad20b4c3ea37069b63f6540",
        "targetPath": "/our-therapy-areas/respiratory-and-immunology/epithelial-science",
        "group_size": 1
      },
      {
        "url": "https://www.astrazeneca.com/our-therapy-areas/respiratory-and-immunology/lupus.html",
        "source": "SITEMAPS",
        "id": "3a1713849c089cbbd660c1cb3d6285277d591344",
        "targetPath": "/our-therapy-areas/respiratory-and-immunology/lupus",
        "group_size": 1
      },
      {
        "url": "https://www.astrazeneca.com/our-therapy-areas/vaccines-and-immune-therapies/covid-19.html",
        "source": "SITEMAPS",
        "id": "6c7c5210a03d1cdf8563234c35b981873bd606c2",
        "targetPath": "/our-therapy-areas/vaccines-and-immune-therapies/covid-19",
        "group_size": 1
      },
      {
        "url": "https://www.astrazeneca.com/our-therapy-areas/vaccines-and-immune-therapies/hMPV.html",
        "source": "SITEMAPS",
        "id": "aeb1b3286cf90b19bb841aec7a2114fdb034b3ef",
        "targetPath": "/our-therapy-areas/vaccines-and-immune-therapies/hmpv",
        "group_size": 1
      },
      {
        "url": "https://www.astrazeneca.com/our-therapy-areas/vaccines-and-immune-therapies/respiratory-syncytial-virus.html",
        "source": "SITEMAPS",
        "id": "e226f875441c5c8be8520434a8f489b42ead05a1",
        "targetPath": "/our-therapy-areas/vaccines-and-immune-therapies/respiratory-syncytial-virus",
        "group_size": 1
      },
      {
        "url": "https://www.astrazeneca.com/partnering.html",
        "source": "SITEMAPS",
        "id": "4895c310e37378025189e5ed2afac432f1661594",
        "targetPath": "/partnering",
        "group_size": 1
      },
      {
        "url": "https://www.astrazeneca.com/partnering/az-suppliers/supplier-contact-form.html",
        "source": "SITEMAPS",
        "id": "61567da2e84f982ead799ee25724ad41ebd26394",
        "targetPath": "/partnering/az-suppliers/supplier-contact-form",
        "group_size": 1
      },
      {
        "url": "https://www.astrazeneca.com/partnering/externally-sponsored-scientific-research-partner-portal/training-centre.html",
        "source": "SITEMAPS",
        "id": "83e7e11c6a2aa0f79a6550e8d3196d5f2e536a22",
        "targetPath": "/partnering/externally-sponsored-scientific-research-partner-portal/training-centre",
        "group_size": 1
      },
      {
        "url": "https://www.astrazeneca.com/patient-reported-outcomes.html",
        "source": "SITEMAPS",
        "id": "a70b827d4d441c82326210d1762cc0c716a781a0",
        "targetPath": "/patient-reported-outcomes",
        "group_size": 1
      },
      {
        "url": "https://www.astrazeneca.com/publication.html",
        "source": "SITEMAPS",
        "id": "837d98cf3d61dd82d352e2e5d932cfe3d626a21d",
        "targetPath": "/publication",
        "group_size": 1
      },
      {
        "url": "https://www.astrazeneca.com/r-d.html",
        "source": "SITEMAPS",
        "id": "f13600bb5d4f7293dba39955ce6e1dd093f0d176",
        "targetPath": "/r-d",
        "group_size": 1
      },
      {
        "url": "https://www.astrazeneca.com/r-d/clinical-innovation.html",
        "source": "SITEMAPS",
        "id": "0f2bac583c11adbec8ecfebd76ee3a89f8391d01",
        "targetPath": "/r-d/clinical-innovation",
        "group_size": 1
      },
      {
        "url": "https://www.astrazeneca.com/r-d/data-science-and-ai.html",
        "source": "SITEMAPS",
        "id": "661a70cb2fc16cfa857b262a2c1323820ff39ba4",
        "targetPath": "/r-d/data-science-and-ai",
        "group_size": 1
      },
      {
        "url": "https://www.astrazeneca.com/r-d/digital-health-revolutionising-healthcare-for-patients.html",
        "source": "SITEMAPS",
        "id": "bd91f519a266ab2c46d109fcc9c12fd542168de4",
        "targetPath": "/r-d/digital-health-revolutionising-healthcare-for-patients",
        "group_size": 1
      },
      {
        "url": "https://www.astrazeneca.com/r-d/glossary.html",
        "source": "SITEMAPS",
        "id": "53a7468a012b819cb34ec621e3d6b0b8f6e05ae1",
        "targetPath": "/r-d/glossary",
        "group_size": 1
      },
      {
        "url": "https://www.astrazeneca.com/r-d/next-generation-therapeutics.html",
        "source": "SITEMAPS",
        "id": "ec3046760900535f65102002632a5f47eede644f",
        "targetPath": "/r-d/next-generation-therapeutics",
        "group_size": 1
      },
      {
        "url": "https://www.astrazeneca.com/r-d/our-approach.html",
        "source": "SITEMAPS",
        "id": "e8ee8b4820d486dae4dcea6f0587b3a1874f95bb",
        "targetPath": "/r-d/our-approach",
        "group_size": 1
      },
      {
        "url": "https://www.astrazeneca.com/r-d/our-approach/stem-at-astrazeneca.html",
        "source": "SITEMAPS",
        "id": "14690ceea5f2ce83147e54fd11ab53c28d506c65",
        "targetPath": "/r-d/our-approach/stem-at-astrazeneca",
        "group_size": 1
      },
      {
        "url": "https://www.astrazeneca.com/r-d/our-strategic-r-d-centres.html",
        "source": "SITEMAPS",
        "id": "60b1bfa1d05bd626934fa75d0c0deb2f3f70a4cd",
        "targetPath": "/r-d/our-strategic-r-d-centres",
        "group_size": 1
      },
      {
        "url": "https://www.astrazeneca.com/r-d/our-technologies.html",
        "source": "SITEMAPS",
        "id": "e7845bef8eb895fc9590a19b4a53efd1bb0023fd",
        "targetPath": "/r-d/our-technologies",
        "group_size": 1
      },
      {
        "url": "https://www.astrazeneca.com/r-d/precision-medicine.html",
        "source": "SITEMAPS",
        "id": "e705d71a7405a11282ddd5d21f85f0b4fc3aaa0e",
        "targetPath": "/r-d/precision-medicine",
        "group_size": 1
      },
      {
        "url": "https://www.astrazeneca.com/r-d/transformative-science.html",
        "source": "SITEMAPS",
        "id": "24a390fae35d9ba61784c8880696f493e00d2fd0",
        "targetPath": "/r-d/transformative-science",
        "group_size": 1
      },
      {
        "url": "https://www.astrazeneca.com/search_results.html",
        "source": "SITEMAPS",
        "id": "777e53411b2e7643efea4d37cadabe81bb7fee8c",
        "targetPath": "/search-results",
        "group_size": 1
      },
      {
        "url": "https://www.astrazeneca.com/sustainability.html",
        "source": "SITEMAPS",
        "id": "683045f1fa83cee1c7b4befcb5bf177e18f0ba61",
        "targetPath": "/sustainability",
        "group_size": 1
      },
      {
        "url": "https://www.astrazeneca.com/sustainability/access-to-healthcare/equitable-access.html",
        "source": "SITEMAPS",
        "id": "c1aaac9756af9dc68e3d3b4a3f0cd82c4aec02bb",
        "targetPath": "/sustainability/access-to-healthcare/equitable-access",
        "group_size": 1
      },
      {
        "url": "https://www.astrazeneca.com/sustainability/access-to-healthcare/health-system-resilience.html",
        "source": "SITEMAPS",
        "id": "d5079f6546a19e9a92f92ea86e4fbef9a55b66eb",
        "targetPath": "/sustainability/access-to-healthcare/health-system-resilience",
        "group_size": 1
      },
      {
        "url": "https://www.astrazeneca.com/sustainability/climate-change/az-forest.html",
        "source": "SITEMAPS",
        "id": "86423429745ab7daaa7d4599faf9229a14727f23",
        "targetPath": "/sustainability/climate-change/az-forest",
        "group_size": 1
      },
      {
        "url": "https://www.astrazeneca.com/sustainability/climate-change/product-sustainability.html",
        "source": "SITEMAPS",
        "id": "0ed159d670c6583bfaa36e18e79a860001ebc0cb",
        "targetPath": "/sustainability/climate-change/product-sustainability",
        "group_size": 1
      },
      {
        "url": "https://www.astrazeneca.com/sustainability/climate-change/renewable-energy.html",
        "source": "SITEMAPS",
        "id": "c8d8467104757aaa27d32c03780a0a335169cbd5",
        "targetPath": "/sustainability/climate-change/renewable-energy",
        "group_size": 1
      },
      {
        "url": "https://www.astrazeneca.com/sustainability/ethics-compliance/animals-in-research.html",
        "source": "SITEMAPS",
        "id": "db86ffb038cbf05ebc6521a713e73bb136909ea0",
        "targetPath": "/sustainability/ethics-compliance/animals-in-research",
        "group_size": 1
      },
      {
        "url": "https://www.astrazeneca.com/sustainability/ethics-compliance/astrazeneca-and-global-transparency.html",
        "source": "SITEMAPS",
        "id": "67c6e5ed0df51464940a743eb820bed47eab6eec",
        "targetPath": "/sustainability/ethics-compliance/astrazeneca-and-global-transparency",
        "group_size": 1
      },
      {
        "url": "https://www.astrazeneca.com/sustainability/ethics-compliance/data-and-ai-ethics.html",
        "source": "SITEMAPS",
        "id": "53a4ca571f1f22e7350147d1bdfcb8d9cfec7107",
        "targetPath": "/sustainability/ethics-compliance/data-and-ai-ethics",
        "group_size": 1
      },
      {
        "url": "https://www.astrazeneca.com/sustainability/ethics-compliance/our-commitment-to-clinical-trial-transparency.html",
        "source": "SITEMAPS",
        "id": "944c05846a80f4c527b4f533bcccf1fccf6415b6",
        "targetPath": "/sustainability/ethics-compliance/our-commitment-to-clinical-trial-transparency",
        "group_size": 1
      },
      {
        "url": "https://www.astrazeneca.com/sustainability/health-equity/community-investment.html",
        "source": "SITEMAPS",
        "id": "03854f51529490362fb51c89bc9d7fe69e656e5d",
        "targetPath": "/sustainability/health-equity/community-investment",
        "group_size": 1
      },
      {
        "url": "https://www.astrazeneca.com/sustainability/health-equity/healthcare-delivery.html",
        "source": "SITEMAPS",
        "id": "cda866cf688cf38c1d204a7267c6f5f06448919b",
        "targetPath": "/sustainability/health-equity/healthcare-delivery",
        "group_size": 1
      },
      {
        "url": "https://www.astrazeneca.com/sustainability/health-equity/healthy-heart-africa.html",
        "source": "SITEMAPS",
        "id": "41838f260a086c96ced98f97eb08fb0d90fe0ba1",
        "targetPath": "/sustainability/health-equity/healthy-heart-africa",
        "group_size": 1
      },
      {
        "url": "https://www.astrazeneca.com/sustainability/health-equity/science.html",
        "source": "SITEMAPS",
        "id": "8a1a7104bee24290d4ac4b06542c8643e474890c",
        "targetPath": "/sustainability/health-equity/science",
        "group_size": 1
      },
      {
        "url": "https://www.astrazeneca.com/sustainability/health-systems-resilience/PHSSR.html",
        "source": "SITEMAPS",
        "id": "164607823c469fd3f9341a936f550c300fc1f43c",
        "targetPath": "/sustainability/health-systems-resilience/phssr",
        "group_size": 1
      },
      {
        "url": "https://www.astrazeneca.com/sustainability/nature/pharmaceuticals-in-the-environment.html",
        "source": "SITEMAPS",
        "id": "6fadf2b02a6086a078e0f8739f47194b38f3ec90",
        "targetPath": "/sustainability/nature/pharmaceuticals-in-the-environment",
        "group_size": 1
      },
      {
        "url": "https://www.astrazeneca.com/sustainability/nature/pharmaceuticals-in-the-environment/EcoPharmacoVigilance-Dashboard.html",
        "source": "SITEMAPS",
        "id": "4a1bc55b26397f9db08eff2bda6c971329fd990f",
        "targetPath": "/sustainability/nature/pharmaceuticals-in-the-environment/ecopharmacovigilance-dashboard",
        "group_size": 1
      },
      {
        "url": "https://www.astrazeneca.com/sustainability/nature/pharmaceuticals-in-the-environment/dashboard-archive.html",
        "source": "SITEMAPS",
        "id": "64202d5de181f651f91d931738b9f4d48865072c",
        "targetPath": "/sustainability/nature/pharmaceuticals-in-the-environment/dashboard-archive",
        "group_size": 1
      },
      {
        "url": "https://www.astrazeneca.com/sustainability/nature/waste-circularity.html",
        "source": "SITEMAPS",
        "id": "a532a41dcc82de9001909d2f1408b061526ab3a3",
        "targetPath": "/sustainability/nature/waste-circularity",
        "group_size": 1
      },
      {
        "url": "https://www.astrazeneca.com/sustainability/nature/water-stewardship.html",
        "source": "SITEMAPS",
        "id": "f932d90623ed7f1c56c871fa2bbf3391ba9b6fd1",
        "targetPath": "/sustainability/nature/water-stewardship",
        "group_size": 1
      },
      {
        "url": "https://www.astrazeneca.com/terms-and-conditions.html",
        "source": "SITEMAPS",
        "id": "8dd816ba0fd271ca4011e9c4382387d270adc67d",
        "targetPath": "/terms-and-conditions",
        "group_size": 1
      },
      {
        "url": "https://www.astrazeneca.com/what-science-can-do.html",
        "source": "SITEMAPS",
        "id": "18ce9eb1f19235bff3e1733fe7ef9d462d10e6db",
        "targetPath": "/what-science-can-do",
        "group_size": 1
      },
      {
        "url": "https://www.astrazeneca.com/what-science-can-do/stories-of-impact.html",
        "source": "SITEMAPS",
        "id": "87fc0a6d187332451ac81c4fc3290d0ef90d9ac6",
        "targetPath": "/what-science-can-do/stories-of-impact",
        "group_size": 1
      },
      {
        "url": "https://www.astrazeneca.com/what-science-can-do/stories-of-impact/early-diagnosis-and-treatment-to-transform-care.html",
        "source": "SITEMAPS",
        "id": "124506ce2528d4c1efb2e3b135aa615dc695b69d",
        "targetPath": "/what-science-can-do/stories-of-impact/early-diagnosis-and-treatment-to-transform-care",
        "group_size": 1
      },
      {
        "url": "https://www.astrazeneca.com/what-science-can-do/topics/covid-19/burden-of-disease.html",
        "source": "SITEMAPS",
        "id": "e86756ccf4922c33a884f82213d863acaefc0fa6",
        "targetPath": "/what-science-can-do/topics/covid-19/burden-of-disease",
        "group_size": 1
      },
      {
        "url": "https://www.astrazeneca.com/what-science-can-do/topics/covid-19/immunobridging-trials.html",
        "source": "SITEMAPS",
        "id": "d9b67246a5b8167884082adb0a87ab614ec2de95",
        "targetPath": "/what-science-can-do/topics/covid-19/immunobridging-trials",
        "group_size": 1
      },
      {
        "url": "https://www.astrazeneca.com/what-science-can-do/topics/covid-19/viral-variants-and-immunocompromised.html",
        "source": "SITEMAPS",
        "id": "a42556b5446c91283079a24a26fadbe861d93357",
        "targetPath": "/what-science-can-do/topics/covid-19/viral-variants-and-immunocompromised",
        "group_size": 1
      }
    ]
  }